GlassScriptPhysician profile
Hope Alexis Stephens
NPI 1376127308
$1,543.02
in general payments reported to CMS, 2019-2025
18 companies · $1,003 in 2025
The $1,003 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $119 · 2023: $171 · 2024: $250 · 2025: $1,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,424.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $240.71 | 2025 | Airsupra, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $166.88 | 2025 | Nucala |
| Genzyme Corporation | $150.28 | 2025 | |
| Novartis Pharmaceuticals Corporation | $127.22 | 2023-2025 | |
| Braeburn INC. | $120.62 | 2024 | Brixadi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.54 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $113.64 | 2025 | Neffy |
| Dynavax Technologies Corporation | $105.61 | 2024 | Heplisav-B |
| Csl Behring | $71.21 | 2025 | Andembry, Hizentra, Privigen |
| Grifols USA, LLC | $61.29 | 2025 | Xembify |
| Uswm, LLC | $59.84 | 2023 | Lucemyra |
| Ionis Pharmaceuticals, INC. | $48.83 | 2025 | Dawnzera |
| Genentech USA, INC. | $37.54 | 2025 | Xolair |
| Lilly USA, LLC | $28.10 | 2025 | Ebglyss |
| Cycle Pharmaceuticals INC | $26.62 | 2025 | Sajazir |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $23.95 | 2025 | Dupixent |
| Alkermes, INC. | $23.89 | 2024 | Vivitrol |
| Galderma Laboratories, L.P. | $18.25 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hope Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.